- Home
- ORGO vs TBPH Comparison
ORGO vs TBPH Comparison
Compare ORGO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- TBPH
- Stock Information
- Founded
- ORGO 1985
- TBPH 2013
- Country
- ORGO United States
- TBPH United States
- Employees
- ORGO N/A
- TBPH N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- TBPH Health Care
- Exchange
- ORGO Nasdaq
- TBPH Nasdaq
- Market Cap
- ORGO 620.3M
- TBPH 699.0M
- IPO Year
- ORGO N/A
- TBPH N/A
- Fundamental
- Price
- ORGO $4.08
- TBPH $14.41
- Analyst Decision
- ORGO Buy
- TBPH Strong Buy
- Analyst Count
- ORGO 3
- TBPH 4
- Target Price
- ORGO $7.33
- TBPH $23.00
- AVG Volume (30 Days)
- ORGO 800.7K
- TBPH 367.5K
- Earning Date
- ORGO 11-06-2025
- TBPH 11-11-2025
- Dividend Yield
- ORGO N/A
- TBPH N/A
- EPS Growth
- ORGO N/A
- TBPH N/A
- EPS
- ORGO N/A
- TBPH 0.26
- Revenue
- ORGO $429,531,000.00
- TBPH $77,205,000.00
- Revenue This Year
- ORGO $2.51
- TBPH $79.82
- Revenue Next Year
- ORGO $25.45
- TBPH N/A
- P/E Ratio
- ORGO N/A
- TBPH $56.32
- Revenue Growth
- ORGO N/A
- TBPH 24.49
- 52 Week Low
- ORGO $2.61
- TBPH $7.88
- 52 Week High
- ORGO $6.71
- TBPH $15.15
- Technical
- Relative Strength Index (RSI)
- ORGO 37.32
- TBPH 58.60
- Support Level
- ORGO $4.12
- TBPH $14.00
- Resistance Level
- ORGO $4.40
- TBPH $15.10
- Average True Range (ATR)
- ORGO 0.24
- TBPH 0.50
- MACD
- ORGO -0.06
- TBPH -0.04
- Stochastic Oscillator
- ORGO 11.96
- TBPH 53.79
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).